#United States #Washington, D.C. #Zepbound #retatrutide #Foundayo

Eli Lilly's Commitment to Revolutionizing Obesity Care at ObesityWeek 2026

Eli Lilly and Company, a leader in the pharmaceutical industry, has unveiled significant findings from its cardiometabolic health portfolio at ObesityWeek 2026, a key event for healthcare professionals focused on obesity treatment. Taking place from November 14-17 in Washington, D.C., Lilly presented promising data on its investigational therapies, including EloraTZP, retatrutide, and Foundayo, emphasizing the importance of holistic obesity management beyond simple weight metrics.

EloraTZP: A Novel Approach Combining Therapies

One of the highlights of Lilly's presentations was the Phase 2 data on EloraTZP, a combination of eloralintide and tirzepatide. Results showed participants achieving an impressive average weight loss of 54.1 lbs (23.3%) over 48 weeks. Moreover, around 60% of participants no longer met the BMI criteria for obesity. The therapy also significantly reduced A1C levels by up to 2.9%, with 77% of participants reaching normal blood sugar levels. This demonstrates EloraTZP's potential not just for weight loss, but also for improving metabolic health in individuals battling obesity and type 2 diabetes.

Transformative Results from Retatrutide

Retatrutide, an investigational triple agonist, also showcased transformative results. Data from trials TRIUMPH-1, TRIUMPH-2, and TRIUMPH-4 revealed substantial benefits for patients suffering from obesity-related conditions such as obstructive sleep apnea (OSA) and knee osteoarthritis. Specifically, retatrutide reduced breathing disruptions in patients with moderate to severe OSA by an average of 36.1 events per hour (60.6%) over 80 weeks. In those with knee osteoarthritis, it alleviated pain significantly, with a reduction of 4.3 points (73.1%) by the 80th week.

Real-World Evidence and Patient Experience with Foundayo

Alongside clinical efficacy, Lily’s Foundayo (orforglipron) was reported as highly user-friendly. In a real-world study, 96-98% of users described Foundayo as simple and convenient, supporting their weight loss journey as part of a reduced-calorie diet and increased physical activity. Furthermore, participants reported tangible benefits, like decreased food cravings and reduced 'food noise', where 74% noted fewer cravings for sugary snacks.

A Holistic Perspective on Obesity Management

The overarching theme from Lilly at ObesityWeek 2026 stressed that effective obesity care transcends merely addressing numerical values on a scale. Kenny Custer, Ph.D. and Executive Vice President of Lilly Cardiometabolic Health, stated, "Obesity care is about more than numbers on the scale; it is about improving overall health and addressing the myriad of ways the disease can affect daily life. Our new evidence reflects a broader view of care, aligning clinical outcomes with the real-world experiences of the patients we serve."

Conclusion: A Future of Hope in Obesity Treatment

As Lilly continues to innovate and conduct clinical trials that showcase diversity and aim to provide distinct treatment options, the groundbreaking data presented at ObesityWeek serves as a beacon of hope for individuals struggling with obesity. With treatments like EloraTZP, retatrutide, and Foundayo, there is a promising future for improved health outcomes that address the multifaceted impacts of this chronic disease. The collaboration between innovative therapies and compassionate patient care is crucial for making strides in this ongoing battle against obesity.